Movetis

Movetis was a pharmaceutical company headquartered in Belgium. It was founded in 2006 as a spin-off from parent company Johnson & Johnson. The company specialized in pharmaceuticals for treating gastro-intestinal disorders.

The primary drug produced by Movetis was Prucalopride (known by the brand name "Resolor") , indicated for cases of chronic constipation.

History

Movetis was founded by Dirk Reyn, Staf Van Reet Jan schuurkes and Remi VandenBroek , and was backed by venture firms Sofinnova Partners, Sofinnova Ventures and Life Sciences Partners. In December 2009, it became a public company with an IPO on the New York Stock Exchange's Euronext.[1] Shortly thereafter, it gained regulatory approval to distribute Resolor in 30 European countries.

In 2010, the company was acquired by British drugmaker Shire Plc for 428 million euros ($559 million).[2]

References
  1. Shire forges $565M buyout deal for Movetis
  2. Shire to buy Belgian drugmaker Movetis for $560mln
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.